C-C MOTIF CHEMOKINE 2

Approval Year

Substance Class	Protein Created by `admin` on `Tue Apr 01 22:27:26 GMT 2025` Edited by `admin` on `Tue Apr 01 22:27:26 GMT 2025`
Protein Type	CYTOKINE
Protein Sub Type
Sequence Origin	HUMAN
Sequence Type	COMPLETE
Record UNII	17I3DH51XQ
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CCL2

Preferred Name

English

C-C MOTIF CHEMOKINE 2

Common Name

English

MONOCYTE CHEMOTACTIC AND ACTIVATING FACTOR

Common Name

English

HC11

Common Name

English

MONOCYTE CHEMOATTRACTANT PROTEIN 1

Common Name

English

SCYA2

Common Name

English

MCP-1

Common Name

English

MONOCYTE CHEMOTACTIC PROTEIN 1

Common Name

English

MONOCYTE SECRETORY PROTEIN JE

Common Name

English

MCP1

Common Name

English

MCAF

Common Name

English

SMALL-INDUCIBLE CYTOKINE A2

Common Name

English

Code System Code Type Description

FDA UNII

17I3DH51XQ

Created by admin on Tue Apr 01 22:27:26 GMT 2025 , Edited by admin on Tue Apr 01 22:27:26 GMT 2025

PRIMARY

UNIPROT

P13500

Created by admin on Tue Apr 01 22:27:26 GMT 2025 , Edited by admin on Tue Apr 01 22:27:26 GMT 2025

PRIMARY

From	To
1_12	1_52
1_11	1_36

Glycosylation Type

HUMAN

Glycosylation Link Type	Site
N	1_14

Related Record Type Details


					FZ7798X3IR

CAMOBUCOL

INHIBITOR -> TARGET

Amount:


					E3DSH8LL4L

VAROGLUTAMSTAT

INHIBITOR OF EXPRESSION->TARGET

Comments:

Inhibit conversion of N-terminal Q to pE. formation of pE was prevented by inhibiting isoQC, CCL2 was more prone to N-terminal degradation, which resulted in less functional CCL2 activity. This had the net effect of decreasing monocyte infiltration in vivo, resulting in decreased lung inflammation,

Interaction Type:

IN-VIVO

Amount:


					6TC1BB2EV9

CARLUMAB

INHIBITOR -> TARGET


					08379P260O

TIPELUKAST

INHIBITOR OF EXPRESSION->TARGET

Amount:


					E3DSH8LL4L

VAROGLUTAMSTAT

INHIBITOR -> TARGET

Comments:

Inhibit conversion of N-terminal Q to pE. formation of pE was prevented by inhibiting isoQC, CCL2 was more prone to N-terminal degradation, which resulted in less functional CCL2 activity. This had the net effect of decreasing monocyte infiltration in vivo, resulting in decreased lung inflammation.

Interaction Type:

IN-VITRO

Amount:


					O7T92N1Y8T

ELSIBUCOL

INHIBITOR OF EXPRESSION->TARGET

Amount:


					JQ11LH711M

BINDARIT

INHIBITOR -> TARGET

Structural Modifications

Modification Type	Location Site	Location Type	Residue Modified	Extent	Fragment Name	Fragment Approval
AMINO_ACID_SUBSTITUTION	[1_1]	SITE_SPECIFIC			PIDOLIC ACID	SZB83O1W42

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
MOL_WEIGHT:NUMBER(CALCULATED)	CHEMICAL
Molecular Formula	CHEMICAL